TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
IBRX

Immunitybio Inc

Healthcare · Biotechnology

8.50$ +0.2% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Immunitybio Inc (IBRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 38.4% of the shares are freely tradable; institutional investors hold 17.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 17.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 62.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 38.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 31.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 1,060Mio.

Largest Shareholders

Institutions

Institutions IBRX
Name Stake (%) Shares Change (%) Date
BlackRock Inc 2.49 26,346,443 +2.9 03/31/2026
State Street Corp 1.67 17,708,103 +7.6 03/31/2026
Vanguard Portfolio Management, LLC 1.54 16,322,844 +0.0 03/31/2026
Vanguard Capital Management, LLC 1.43 15,127,714 +0.0 03/31/2026
D. E. Shaw & Co LP 1.09 11,551,019 -8.1 06/30/2026
Two Sigma Investments LLC 1.05 11,097,106 +153.0 06/30/2026

Funds

Funds IBRX
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 1.24 13,151,931 -1.1 08/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 1.10 11,639,206 +0.3 07/31/2026
iShares Russell 2000 ETF 0.93 9,808,491 -0.6 08/31/2026
Vanguard Small Cap Index 0.80 8,429,651 +0.3 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?